Drugs / TissueGene-C
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03203330 Comparator | Oct 2018 → Jul 2024 overdue | osteoarthritis, knee | Kolon TissueGene, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TissueGene-C | “TissueGene-C” NCT03203330 ↗ |
| Known as | TG-C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03203330 ↗ |
| Modality | Cell therapy | “2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.” NCT03203330 ↗ |
| Route | Other | “single intra-articular injection” NCT03203330 ↗ |